Understanding the Procedure

What is CRS + HIPEC?

Some abdominal cancers spread not through the bloodstream but across the peritoneum — the thin membrane lining the abdominal cavity. This is called peritoneal carcinomatosis or peritoneal surface malignancy. Ordinary intravenous chemotherapy struggles to reach these deposits, because the peritoneum has a poor blood supply.

HIPEC tackles the problem in two stages, in one operation. First, cytoreductive surgery (CRS) — the surgeon meticulously removes every visible tumour deposit from the peritoneal surfaces and affected organs. This can take many hours.

Then comes HIPEC — Hyperthermic Intraperitoneal Chemotherapy. Heated chemotherapy (around 41–43 °C) is circulated throughout the abdominal cavity for 30–90 minutes, reaching every surface directly. The heat itself damages cancer cells and makes the chemotherapy far more effective, while keeping most of the drug inside the abdomen rather than the bloodstream.

The combination targets what each alone cannot: surgery clears visible disease, and heated chemotherapy destroys the microscopic cells left behind. Success depends on achieving a complete cytoreduction.

Why "complete cytoreduction" is everything

HIPEC only works if the surgeon can remove all visible tumour first — heated chemotherapy penetrates just 2–3 mm. This is why patient selection and surgical completeness (the CC score) matter more than almost anything else, and why this operation belongs in experienced, high-volume hands. The goal is always CC-0: no visible disease remaining.

Indications

Who is HIPEC for?

HIPEC is not for every abdominal cancer. It is most effective when disease is confined to the peritoneal surfaces and can be completely removed. The strength of evidence differs by tumour type, so each indication is weighed individually at the tumour board.

Disease-wise indications, evidence & standard HIPEC regimen
Cancer / Disease	Role of CRS + HIPEC	Evidence	Key trial	Typical HIPEC drug
Pseudomyxoma Peritonei	Standard of care; potentially curative with complete cytoreduction	Strong	Large international registries	Mitomycin-C
Appendiceal cancer (mucinous & non-mucinous)	Well-established; resection of peritoneal disease + HIPEC	Strong	Registry & cohort data	Mitomycin-C
Peritoneal mesothelioma	Standard of care at specialist centres; markedly improves survival	Strong	Multi-institutional series	Cisplatin ± Doxorubicin
Colorectal peritoneal metastases	Complete cytoreduction is the key benefit; HIPEC used selectively	Selective	PRODIGE-7 (2021)	Oxaliplatin / Mitomycin-C
Ovarian cancer (interval, selected)	Survival benefit when added to interval debulking after chemotherapy	Supported	van Driel, NEJM 2018	Cisplatin
Gastric cancer (selected)	Limited peritoneal disease / selected cases; evidence still evolving	Investigational	GASTRIPEC; ongoing trials	Mitomycin-C / Cisplatin

Drugs and timing are individualised per tumour type, prior chemotherapy and renal function, and decided at the multidisciplinary tumour board. Perfusion is typically delivered at 41–43 °C for 30–90 minutes.

When HIPEC is not advised

HIPEC is generally not suitable when disease is too extensive to remove completely (very high PCI), when cancer has spread outside the abdomen (liver, lungs, distant nodes), or when a patient is not fit enough for a long operation. Recognising this honestly is part of good care — offering HIPEC where it cannot help does harm. A frank selection assessment protects you.

The Operation

How CRS + HIPEC is performed

This is one of the longest and most complex operations in surgical oncology — often 8 to 12 hours. It is delivered by an experienced team with specialist anaesthesia and critical-care support.

Rectal Cancer Surgery - Dr. Vinod T. Gore

Step 1

Exploration & PCI scoring

The abdomen is opened and fully assessed. The Peritoneal Cancer Index (PCI, 0–39) measures how much disease is present across 13 regions — confirming whether complete removal is achievable.

Step 2

Cytoreductive surgery

Every visible tumour deposit is removed — stripping peritoneal surfaces (peritonectomy) and, where needed, resecting involved bowel, omentum, spleen or other organs. The aim is CC-0.

Step 3

Heated chemotherapy perfusion

Catheters circulate chemotherapy heated to 41–43 °C throughout the abdomen for 30–90 minutes, reaching every surface. The drug and timing depend on the cancer type.

Step 4

Reconstruction & recovery

Any bowel joins are completed, the abdomen is closed, and recovery begins in intensive care. A hospital stay of around two weeks is usual.

PCI score (0–39) CC score (CC-0 / CC-1) Peritonectomy Mitomycin-C / Oxaliplatin / Cisplatin 41–43 °C perfusion ICU recovery

Peritoneal Cancer Index (PCI) — 13 regions × lesion size
Region (0–12)	Area assessed	Lesion Size score	Meaning
0–8	Central, right/left upper & lower, flanks, epigastrium, pelvis	LS 0	No tumour visible
9–12	Upper & lower jejunum, upper & lower ileum	LS 1	Nodules up to 0.5 cm
Each of the 13 regions is scored LS 0–3 →		LS 2	Nodules 0.5–5 cm
Total PCI = sum of all regions (0–39)		LS 3	Nodules > 5 cm or confluent

Reading the total (Sugarbaker): lower PCI predicts a higher chance of complete cytoreduction and better outcomes. As a general guide, colorectal peritoneal disease is most favourable at PCI < 20 (and especially < 12); pseudomyxoma can be resected at much higher indices. PCI is an aid to judgement, weighed with disease type, location and fitness — not a rigid cut-off.

Completeness of Cytoreduction (CC) score
Score	Residual disease after surgery	Prognostic meaning
CC-0	No visible residual tumour	Optimal — the goal
CC-1	Residual nodules ≤ 2.5 mm	Complete — HIPEC can penetrate
CC-2	Residual nodules 2.5 mm – 2.5 cm	Incomplete
CC-3	Residual nodules > 2.5 cm	Incomplete

Why CC matters most: heated chemotherapy penetrates only 2–3 mm, so it can only sterilise microscopic disease. The survival benefit of the whole operation depends on achieving CC-0 or CC-1. If complete cytoreduction cannot be achieved, HIPEC offers little — which is why honest patient selection comes first.

The Evidence — Key Lessons

Reading the trials honestly

The disease table above summarises the evidence and key trial for each indication. Two findings deserve a closer word, because they shape how HIPEC should — and should not — be used.

PRODIGE-7

The benefit is the complete surgery

This French randomised trial (2021) found that in colorectal peritoneal metastases the survival benefit came chiefly from complete cytoreductive surgery itself; adding oxaliplatin HIPEC did not improve overall survival. It refined — not removed — the role of HIPEC, and confirmed that complete cytoreduction and careful patient selection are what drive results.

No prophylaxis

HIPEC is not preventive

PROPHYLOCHIP and COLOPEC tested "prophylactic" or "second-look" HIPEC in high-risk colorectal cancer and showed no benefit. HIPEC is therefore reserved for established, resectable peritoneal disease — not used to prevent it.

Bottom line

Selection-driven, not one-size-fits-all

Across every trial the message is consistent: outcomes depend on the right tumour type, low-volume disease (low PCI) and complete cytoreduction (CC-0/CC-1). Offered to the right patient, CRS + HIPEC delivers results no other treatment can.

Recovery & Risks

What to expect afterwards

CRS + HIPEC is major surgery with a real recovery. Being prepared for it — and being cared for by a team that does this regularly — makes the difference.

Hospital

Around two weeks in hospital

Starting with a few days in intensive care. Eating and mobility are reintroduced gradually as the bowel recovers.

Recovery

Two to three months to full strength

Tiredness is normal for some weeks. Most people return steadily to normal activity over two to three months, guided by follow-up.

Risks

Significant but manageable

As a long operation, it carries risks including bleeding, infection, bowel-join leak and blood-count effects from chemotherapy. High-volume teams keep complication rates low and manage them promptly.

Follow-up

Regular surveillance

Scans, tumour markers and clinical review on a planned schedule, often combined with systemic chemotherapy depending on the cancer type.

Patient Questions

HIPEC — answered plainly

For some cancers — especially pseudomyxoma peritonei and appendiceal disease — complete CRS + HIPEC can be curative, with many patients living disease-free for years. For others, such as colorectal peritoneal metastases, it offers significant long-term control in selected patients. Whether cure is realistic depends on the tumour type, the volume of disease, and whether all of it can be removed.

Suitability rests on three things: the cancer type, the amount of peritoneal disease (PCI score on imaging and at surgery), and whether complete removal is achievable, plus your overall fitness for a long operation. Disease outside the abdomen usually rules HIPEC out. The decision is made at a multidisciplinary tumour board, not by one person alone.

Heat does two things: it directly damages cancer cells, and it makes the chemotherapy penetrate deeper and work more powerfully. Delivering it inside the abdomen also concentrates the drug exactly where the disease is, while limiting how much reaches the rest of the body.

The PRODIGE-7 trial showed that for colorectal peritoneal disease, the benefit came mainly from the complete surgery, and that adding oxaliplatin HIPEC did not improve survival further. It didn't say surgery is useless — quite the opposite. It sharpened our understanding: complete cytoreduction in well-selected patients is what helps, and we apply HIPEC thoughtfully rather than to everyone.

The surgery itself often takes 8–12 hours, depending on how much disease must be removed. A hospital stay of around two weeks is typical, including a few days in intensive care, with full recovery over two to three months.

CRS + HIPEC is performed at a fully equipped hospital with intensive care and specialist anaesthesia. Dr. Gore consults at Silver Leaf Clinic, Hadapsar, and operates at Sahyadri Manipal Hospital, Pune. Bring all scans and reports to your consultation so suitability can be assessed.

This page is general information, not personal medical advice. Suitability for CRS + HIPEC is always decided individually at a multidisciplinary tumour board. Please bring all scans, histopathology and previous operative notes to your consultation.

Silver Leaf Clinic · Hadapsar, Pune

Discuss whether HIPEC is right for you

If you or a family member has peritoneal spread from an abdominal cancer, an early specialist opinion matters — suitability for HIPEC depends on acting before disease becomes too extensive. Please bring all CT/MRI/PET scans, biopsy and histopathology reports, and any previous operative notes — ideally on CD or shared via WhatsApp in advance.

Dr. Gore Direct / WhatsApp

84118 08284

📍 Clinic Address

511, City Centre, Solapur Road, Opp. Vaibhav Theatre, Hadapsar, Pune 411028

📍 Open in Google Maps →

Monday – Saturday10:00 AM – 6:00 PM

SundayBy prior appointment

Surgical Hospital

Sahyadri Manipal Hospital, Pune · Robotic Cancer Surgery Centre of Excellence